OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

Miles Wang, a researcher at OpenAI, is leaving the company to launch a startup focused on developing AI models for drug discovery. The startup is in discussions to raise approximately $200 million at a valuation of $2 billion, according to sources familiar with the matter.

The new company plans to apply artificial intelligence techniques to the pharmaceutical industry, aiming to accelerate the discovery and development of new drugs. Specific details about the technology, target diseases, or timeline have not been disclosed. The funding round, if completed, would value the startup at $2 billion based on the amount raised and the valuation terms.

The move highlights ongoing investor interest in applying AI to drug discovery, a field that has attracted significant venture capital in recent years.